Selected Publications

Martei YM, Obasohan M, Mokokwe L, Ralefala T, Mosepele M, Gross R, Barg FK.: Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana. Oncologist 28: e1230-e1238, Dec 2023.

O'Neil DS, Martei YM, Crew KD, Castillo BS, Costa P, Lim T, Michel A, Rubin E, Goel N, Hurley J, Lopes G, Antoni MH.: Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV. JAMA Netw Open 6: e2346223, Dec 2023.

Kizub DA, Naik S, Abogan AA, Pain D, Sammut S, Shulman LN, Martei YM.: Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda. Oncologist 27(11): 958-970, Nov 2023 Notes: DOI: 10.1093/oncolo/oyac143

Chasimpha S, Dos Santos Silva I, Martei YM, Grover S, Cubasch H, McCormack V.: Survival Disparities Between Patients with Breast Cancer With and Without HIV: A Research Framework. JCO Glob Oncol 2023.

Motlokwa PK, Tsima BM, Martei YM, Ralefala T, Galebole F, Stephens-Shields AJ, Grover S, Gross R.: Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting In Sub-Saharan Africa. JCO Glob Oncol 8: e2100439, Aug 2022 Notes: DOI: 10.1200/GO.21.00439

Martei YM, Narasimhamurthy M, Setlhako DI, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman LN, Grover S, DeMichele A.: Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy. JCO Glob Oncol 8: e2200016. May 2022 Notes: DOI: 10.1200/GO.22.00016

Martei YM, Grover S, Narasimhamurthy M, Setlhako DI, Ayane GN, Ralefala TB, Chiyapo SP, Gross R, DeMichele A, Shulman LN : Relative dose intensity and pathologic response rates in HIV-infected and HIV-uninfected breast cancer patients who received neoadjuvant chemotherapy. Journal of Clinical Oncology 18(15 Suppl e19140): e2200016, May 2022.

Martei YM, Clark AS.: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor-Positive, ERBB2-Negative Breast Cancer Treatment. JAMA Netw Open 5: e224380, Apr 2022.

Martei YM, Dauda B, Vanderpuye V.: Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal. BMC Cancer 22(1): 306, Mar 2022.

Razis E, Kassapian M, Andriakopoulou C, Martei YM, Zurn SJ, Hammad N, Romero Y, Dafni U, Ilbawi AM, Trapani D.: Essential medicines list in national cancer control plans: a secondary analysis from a global study. Lancet Oncol 23(3): e144-154, Mar 2022.